Ensysce Biosciences Inc
Ensysce Biosciences Inc (ENSC) is a micro-cap biotechnology company focused on developing drug-delivery technologies and pharmaceutical formulations. With a market capitalisation around $6.9 million, it sits at the speculative end of the biotech spectrum; its value is driven largely by R&D progress, partnerships and regulatory milestones rather than steady revenue. Investors should expect pronounced share-price volatility, limited liquidity and binary outcomes tied to clinical results or licensing deals. This profile can appeal to those seeking high-risk, high-reward opportunities in early-stage biopharma, but it is important to balance potential upside against the risk of capital loss. Do your own research, review the company’s filings and recent announcements, and consider the stock only as part of a diversified portfolio. This information is general and educational, not personalised investment advice.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Ensysce Biosciences' stock, anticipating a significant rise in value.
Financial Health
Ensysce Biosciences is generating modest revenue, cash flow, and has a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ENSC
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Early-stage potential
The company’s R&D progress and partnerships can be catalysts for value, though outcomes are uncertain and timelines may be long.
High volatility risk
With a small market cap and limited liquidity, share prices can swing widely; suitable only for risk-tolerant investors.
Regulatory milestones matter
Clinical and regulatory updates can be decisive for valuation; keep an eye on filings and press releases for news, while noting possible delays.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
